Meeting
2013 ASCO Annual Meeting
Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).
Authors
Martin R. Stockler
The University of Sydney, Sydney, Australia
Martin R. Stockler , Felix Hilpert , Michael Friedlander , Madeleine King , Lari B. Wenzel , Chee Lee , Florence Joly , Nikolaus De Gregorio , Jose Angel Arranz Arija , Mansoor Raza Mirza , Roberto Sorio , Ulrich Freudensprung , Vesna Sneller , Gill Hales , Eric Pujade Lauraine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT00976911
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5542)
DOI
10.1200/jco.2013.31.15_suppl.5542
Abstract #
5542
Poster Bd #
44F
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer.
First Author: Gordon Taylor Moffat
Poster
2015 ASCO Annual Meeting
Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.
First Author: Aristotelis Bamias
Poster
2014 ASCO Annual Meeting
Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.
First Author: Antonio Gonzalez-Martin
Poster
2022 ASCO Annual Meeting
PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer.
First Author: Judith Michels